ITOS vs. SDGR, EVO, OCUL, VERA, ETNB, BHVN, ANIP, MESO, EWTX, and JANX
Should you be buying iTeos Therapeutics stock or one of its competitors? The main competitors of iTeos Therapeutics include Schrodinger (SDGR), Evotec (EVO), Ocular Therapeutix (OCUL), Vera Therapeutics (VERA), 89BIO (ETNB), Biohaven (BHVN), ANI Pharmaceuticals (ANIP), Mesoblast (MESO), Edgewise Therapeutics (EWTX), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical products" industry.
iTeos Therapeutics vs. Its Competitors
iTeos Therapeutics (NASDAQ:ITOS) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.
In the previous week, Schrodinger had 6 more articles in the media than iTeos Therapeutics. MarketBeat recorded 8 mentions for Schrodinger and 2 mentions for iTeos Therapeutics. iTeos Therapeutics' average media sentiment score of 0.51 beat Schrodinger's score of 0.20 indicating that iTeos Therapeutics is being referred to more favorably in the media.
iTeos Therapeutics has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500.
iTeos Therapeutics has a net margin of 0.00% compared to Schrodinger's net margin of -83.39%. iTeos Therapeutics' return on equity of -21.37% beat Schrodinger's return on equity.
97.2% of iTeos Therapeutics shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 12.5% of iTeos Therapeutics shares are owned by company insiders. Comparatively, 8.6% of Schrodinger shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
iTeos Therapeutics currently has a consensus price target of $15.86, suggesting a potential upside of 55.92%. Schrodinger has a consensus price target of $33.25, suggesting a potential upside of 58.64%. Given Schrodinger's stronger consensus rating and higher probable upside, analysts clearly believe Schrodinger is more favorable than iTeos Therapeutics.
iTeos Therapeutics has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
iTeos Therapeutics beats Schrodinger on 9 of the 16 factors compared between the two stocks.
Get iTeos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ITOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
iTeos Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ITOS) was last updated on 7/6/2025 by MarketBeat.com Staff
